Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer's Disease (AD) at the LD Micro Conference on June 7, 2023

Author's Avatar
May 22, 2023

Coya+Therapeutics%2C+Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance Treg function, including biologics and cell therapies, announced today that it will report new biomarker and brain imaging data from its+open-label+proof-of-concept+clinical+study+for+COYA+301+in+patients+with+Alzheimer%26rsquo%3Bs+Disease at the LD Micro Conference: